Get the Stockscreener App
14.10
5.69%
-0.85
Cullinan Therapeutics Inc stock is traded at $14.10, with a volume of 590.35K.
It is down -5.69% in the last 24 hours and down -31.52% over the past month.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
See More
Previous Close:
$14.95
Open:
$14.86
24h Volume:
590.35K
Relative Volume:
0.61
Market Cap:
$907.40M
Revenue:
$22.39M
Net Income/Loss:
$-221.04M
P/E Ratio:
-3.7961
EPS:
-3.7143
Net Cash Flow:
$-178.65M
1W Performance:
-13.23%
1M Performance:
-31.52%
6M Performance:
-1.05%
1Y Performance:
+80.08%
1-Day Range:
$14.07
$14.93
1-Week Range:
$14.07
$16.46
52-Week Range:
$6.7318
$23.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
14.10 | 907.40M | 22.39M | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | Citigroup | Buy |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Aug-21-25 | Resumed | H.C. Wainwright | Buy |
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Form 8K Cullinan Therapeutics, Inc For: 2 October By Investing.com - Investing.com South Africa
Up to $100M hinges on first-line approval as Cullinan (CGEM) starts a lung cancer drug submission. - Stock Titan
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Has Consensus Price Target of $33.71 According to Analysts - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance UK
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program - GlobeNewswire Inc.
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases - Seeking Alpha
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance Australia
510,325 Shares in Cullinan Therapeutics, Inc. $CGEM Purchased by Bank of America Corp DE - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 7.1%Here's What Happened - MarketBeat
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - GlobeNewswire Inc.
Cullinan Therapeutics (NasdaqGS:CGEM) Stock Price - Simply Wall Street
Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Potential Upside of Over 57% Ignites Investor Interest - DirectorsTalk Interviews
Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen - MarketBeat
EGFR-NSCLC Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innova - Barchart.com
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - Investing News Network
Cullinan Therapeutics to Present Phase 3 REZILIENT3 Interim Data on Zipalertinib Plus Chemotherapy at WCLC 2026, Host Investor Event - Quiver Quantitative
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - The Manila Times
Cullinan Therapeutics to Host Virtual Analyst and Investor - GlobeNewswire
Cullinan Therapeutics CSO Jennifer Michaelson Executes 8,000 Share Sale Under 10b5-1 Plan - Kalkine Media
Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics (CGEM) insider sells 8,000 shares under pre-arranged plan - Stock Titan
171,031 Shares in Cullinan Therapeutics, Inc. $CGEM Bought by Bank of New York Mellon Corp - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Corient Private Wealth LP Takes $970,000 Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
The Manufacturers Life Insurance Company Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
CGEM Should I Buy - Intellectia AI
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded to Hold at Wall Street Zen - MarketBeat
Moore Capital Management LP Raises Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Algert Global LLC Sells 72,880 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
BlackRock Inc. Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - marketbeat.com
Connor Clark & Lunn Investment Management Ltd. Takes Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Elmind Capital LP Purchases New Shares in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Boone Capital Management LLC Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics shows strong multi-asset pipeline with key drug milestones boosting funding prospects. - Pluang
Bank of America Corp DE Acquires 170,417 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Deutsche Bank AG Purchases Shares of 382,840 Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Cullinan (CGEM) Quarterly Figures: Reported EPS Tops Expectations at the Close; After Results: The Share Price Adds 0.65% in the Latest SessionEarnings Yield Analysis - vinanet.vn
Cullinan (CGEM) Quarterly Figures: Reported EPS Tops Expectations at the Close; After Results: The Share Price Adds 0.65% in the Latest SessionCapex Guidance - vinanet.vn
Blue Owl Capital Holdings LP Invests $28.04 Million in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Tokyo’s Taiho and Cullinan Announce Positive Phase 3 Lung Cancer Results - geneonline.com
Is Cullinan Therapeutics (CGEM) Fully Valued After Its Phase 3 Trial Win? - simplywall.st
Taiho, Cullinan trial results selected for lung cancer conference By Investing.com - Investing.com Australia
Cullinan Therapeutics (CGEM) to Present Phase 3 REZILIENT3 Trial - GuruFocus
Taiho, Cullinan trial results selected for lung cancer conference - Investing.com
Taiho, Cullinan trial results selected for lung cancer conference By Investing.com - Investing.com India
Taiho, Cullinan trial results selected for lung cancer conference By Investing.com - Investing.com UK
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer - marketscreener.com
Cullinan's lung cancer trial met its main goal; results are set for presentation in September - Stock Titan
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cullinan Therapeutics Inc Stock (CGEM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer |
Sep 08 '26 |
Sale |
21.57 |
8,000 |
172,560 |
158,844 |
| JENNIFER MICHAELSON | Officer |
Sep 08 '26 |
Proposed Sale |
22.09 |
8,000 |
176,720 |
0 |
| JENNIFER MICHAELSON | Officer |
Aug 13 '26 |
Proposed Sale |
19.60 |
30,000 |
588,000 |
0 |
| Michaelson Jennifer | Chief Scientific Officer |
Aug 13 '26 |
Option Exercise |
4.30 |
30,000 |
129,000 |
192,844 |
| Michaelson Jennifer | Chief Scientific Officer |
Aug 13 '26 |
Sale |
20.26 |
30,000 |
607,800 |
162,844 |
| Michaelson Jennifer | Chief Scientific Officer |
Jul 06 '26 |
Sale |
17.82 |
8,000 |
142,560 |
162,844 |
| JENNIFER MICHAELSON | Officer |
Jul 06 '26 |
Proposed Sale |
17.63 |
8,000 |
141,040 |
0 |
| Michaelson Jennifer | Chief Scientific Officer |
Jul 06 '26 |
Option Exercise |
4.30 |
4,000 |
17,200 |
170,844 |
| Michaelson Jennifer | Chief Scientific Officer |
May 05 '26 |
Option Exercise |
4.30 |
4,000 |
17,200 |
174,844 |
| Michaelson Jennifer | Chief Scientific Officer |
May 05 '26 |
Sale |
14.62 |
8,000 |
116,996 |
166,844 |
4.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):